Clinical trials using other antigen-targeting CAR-T cell regimens in MM, which are targeting CD38, SLAMF7, CD44v, CD56, GPRC5D, transmembrane activator and CAML interactor (TACI), Lewis Y, and NY-ESO-1, as well as preclinical studies targeting CD229 (SLAMF3), integrin β7, CD70, and CD1d, are in progress [23,34,77,78,79]. This evidence concerns the gene LY9 and Miyoshi myopathy.